Navigation Links
Cepheid to Webcast Upcoming Financial Presentations
Date:8/22/2008

SUNNYVALE, Calif., Aug. 22 /PRNewswire-FirstCall/ -- Cepheid (Nasdaq: CPHD) today announced that its executives will be speaking at the following investor conferences, and invited investors to participate via webcast.

Thomas Weisel Partners Healthcare Conference, Boston, MA

Wednesday, September 3, 2008 at 2.05 p.m. Eastern Time

R.W. Baird Small Cap Healthcare Conference, New York, NY

Wednesday, September 10, 2008 at 9.00 a.m. Eastern Time

UBS Global Life Sciences Conference, New York, NY

Tuesday, September 23, 2008 at 9.00 a.m. Eastern Time

Accessing Webcasts

To access the live webcasts for these events, please visit Cepheid's website at http://www.cepheid.com/investors at least 15 minutes before the schedule start time to download any necessary audio or plug-in software. A replay of the webcast will be available shortly following the presentation and will remain available for at least 90 days.

About Cepheid

Cepheid (Nasdaq: CPHD), based in Sunnyvale, Calif., is an on-demand molecular diagnostics company that develops, manufactures, and markets fully-integrated systems and tests for genetic analysis in the clinical, industrial and biothreat markets. The Company's systems enable rapid, sophisticated genetic testing for organisms and genetic-based diseases by automating otherwise complex manual laboratory procedures. Cepheid's easy-to-use systems integrate a number of complicated and time-intensive steps, including sample preparation, DNA amplification and detection, which enable the analysis of complex biological samples in its proprietary test cartridges. Through its stro
'/>"/>

SOURCE Cepheid
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Cepheid Introduces GeneXpert(R) Infinity-48 System at 2008 American Association of Clinical Chemistry Meeting
2. Cepheid Reports Second Quarter Revenue of $42.1 Million
3. Cepheid to Webcast Analyst Event
4. Cepheid Schedules Fiscal 2008 Second Quarter Financial Results Announcement and Webcast
5. Noted Molecular Epidemiologist Joins Cepheid to Head Healthcare Associated Infection Consortium Program
6. Cepheid Market Reach Extended with Licenses in Canada and Registrations in Mexico
7. Cepheid Signs Group Purchasing Contract with Novation, the Nations Largest Healthcare Contracting Organization
8. Cepheid to Present at the Robert W. Baird Growth Stock Conference and the Bank of America Healthcare Conference
9. Cepheid Schedules Teleconference and Webcast for First Quarter 2008 Results
10. Cepheid to Present at Cowen and Companys 28th Annual Healthcare Conference
11. Cepheid Reports Fourth Quarter and Full Year 2007 Results

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/6/2009)...OOK, N.Y., Nov. 6 BioSpe...harmaceutical company developing first-in-class co...ncial results for the third quarter ended Septembe...in September of this year, the FDA,s Arthritis Adv... of 12-0, the approval of XIAFLEX(TM) for the trea...
(Date:11/6/2009)...IENNA, Austria, November 6 EUCODIS...nufacturing, and marketing enzymes for the,chemica...o a research,agreement with Bio Sidus, the leading..., The agreement gives EUCODIS Bioscience exclu...t - to Bio Sidus, proprietary collection of,psychr...
(Date:11/6/2009)...RY, Nov. 6 /PRNewswire-FirstCall/ - Oncolytics Bio...the "Company") today announced updated results fro...atients with sarcomas metastatic to the lung in a ...Tissue Oncology Society Meeting held in Miami Beac...resentation, entitled "A Phase II Study of Intrave...
(Date:11/5/2009)...ORTATION -- Gone hybrid . . . , Fuel economy r... now posted at the www.fueleconomy.gov web site,... maintains for the U.S. Department of Energy and t...he top 10 vehicles on the best fuel economy list a...PG city; 48 highway). "This list proves that hybri...
Breaking Biology Technology:Reissue with Tables: BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 2Reissue with Tables: BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 3Reissue with Tables: BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 4Reissue with Tables: BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 5Reissue with Tables: BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 6EUCODIS Bioscience to Explore Novel Enzymatic Activities in Antarctic Bacteria Library From Bio Sidus 2Oncolytics Biotech(R) Inc. Collaborators Present Positive Phase II Sarcoma Trial Results at CTOS Annual Meeting 2Oncolytics Biotech(R) Inc. Collaborators Present Positive Phase II Sarcoma Trial Results at CTOS Annual Meeting 3November 2009 story tips from the US Department of Energy's Oak Ridge National Laboratory 2November 2009 story tips from the US Department of Energy's Oak Ridge National Laboratory 3
...ent Response to Novel Beta Blocker ...dolol, an investigational,pharmacologically unique...reduces hospitalization and death among heart fail...ing to results of a large DNA study presented,toda...ailure Society of,America. Researchers found that ...
...US$10 million received based on the positive revie...ultiple sclerosis trial - EDMONTON, Sept. 22 /PRN..., a leading developer in the treatment of multiple...ved the US$10 million milestone payment from its,p...ment is based on the previously announced positive...
...l Systems and BrainLAB enabling, non-invasive tr...vous system, PALO...ctors around the globe are turning more and,more t... for the treatment,of cancer and other conditions.... Systems (NYSE: VAR ) and BrainLAB, doctors are p...
Other Biology Technology:Bucindolol Significantly Reduces Hospitalization and Death in Heart Failure Patients With Very Favorable Genotypes 2Bucindolol Significantly Reduces Hospitalization and Death in Heart Failure Patients With Very Favorable Genotypes 3BioMS Medical announces receipt of milestone payment from Eli Lilly and Company 2Non-Invasive Radiosurgery with Novalis Tx(TM) Platform Rolling Out Worldwide 2Non-Invasive Radiosurgery with Novalis Tx(TM) Platform Rolling Out Worldwide 3Non-Invasive Radiosurgery with Novalis Tx(TM) Platform Rolling Out Worldwide 4Non-Invasive Radiosurgery with Novalis Tx(TM) Platform Rolling Out Worldwide 5
(Date:11/4/2009)...HILADELPHIA Although scientists are reluctant to ...n method, evidence continues to grow about its pro...published in Cancer Prevention Research , a journ..., which suggests some reduction in oral cancer. ,...f medicine in the Department of Thoracic/Head and ...
(Date:11/4/2009)...eavy traffic corridors in the cities of Long Beach...roportion of preventable childhood asthma, and the...n the disease has likely been underestimated, acco... California (USC). , The study, which appears i...blic Health , estimated that nine percent of all c...
(Date:11/4/2009)...ancouver, BC - Lowly bacteria, it turns out, hold ...turing plants around the world clean up toxic wast..., specifically RDX, were invented back in World Wa...decades. These high-energy compounds are often us...ful version of TNT. , But with increased knowl...
Breaking Biology News(10 mins):Does green tea prevent cancer? Evidence continues to brew, but questions remain 2USC study finds big air pollution impacts on local communities 2Genomic research will enable greener cleanup of military explosive test sites 2BioCryst Awarded Additional 2477 2 Million by the U S Department of Health 26 Human Services To Develop Peramivir for Influenza 57736 1BioCryst Awarded Additional 2477 2 Million by the U S Department of Health 26 Human Services To Develop Peramivir for Influenza 57736 2BioCryst Awarded Additional 2477 2 Million by the U S Department of Health 26 Human Services To Develop Peramivir for Influenza 57736 3BioCryst Awarded Additional 2477 2 Million by the U S Department of Health 26 Human Services To Develop Peramivir for Influenza 57736 4BioCryst Awarded Additional 2477 2 Million by the U S Department of Health 26 Human Services To Develop Peramivir for Influenza 57736 5DOR BioPharma Announces 249 4 Million NIH Grant Award to Develop Thermostable and Rapidly Acting Vaccines 57734 1DOR BioPharma Announces 249 4 Million NIH Grant Award to Develop Thermostable and Rapidly Acting Vaccines 57734 2DOR BioPharma Announces 249 4 Million NIH Grant Award to Develop Thermostable and Rapidly Acting Vaccines 57734 3DOR BioPharma Announces 249 4 Million NIH Grant Award to Develop Thermostable and Rapidly Acting Vaccines 57734 4DOR BioPharma Announces 249 4 Million NIH Grant Award to Develop Thermostable and Rapidly Acting Vaccines 57734 5DOR BioPharma Announces 249 4 Million NIH Grant Award to Develop Thermostable and Rapidly Acting Vaccines 57734 6AEterna Zentaris Announces Completion of Phase 1 Study with Oral AEZS 112 in Cancer 14165 1AEterna Zentaris Announces Completion of Phase 1 Study with Oral AEZS 112 in Cancer 14165 2AEterna Zentaris Announces Completion of Phase 1 Study with Oral AEZS 112 in Cancer 14165 3
...ug development : only "lucrative","markets" get ex...ve,seen very promising drugs candidates or related...de with it, even if millions would have,been saved...is to find,a drug candidate that affect a "profita...ne. PLoS Medecine has an article about a possible,...
...f the Chinese hybrid rice genome, which was publis...s have recently finished the fine map of the rice ...e of PLoS Biology (Vol.3 Issue 2, 2005), scientist...eported a "much improved, near-complete genome ana...sativa." , The fine maps of the rice genome seque...
...lar signaling mechanism whose existence has been,k...since the,identification of a mutant strain of Dro...Hunt Morgan’s lab in 1910. Later studies,revealed ...t extends,through both sides of the cell membrane ...partner, such as the protein Delta, presented,on t...
Other Biology News:Finding Cures For Tropical Diseases: Is Open Source An Answer? 2Whole genome fine map of rice completed 2Bound for destruction: Ubiquitination protects against improper Notch signaling 2Bound for destruction: Ubiquitination protects against improper Notch signaling 3
Mae II from Roche Applied Science
...etase Activity Kit ADAM17 Activity Kit TNF-α...T FROM LIGHT. AVOID FREEZE/THAW CYCLES. The InnoZy...itive assay designed to measure human TACE activit...creening enzyme inhibitors. An Anti-Human TACE-Coa...
...garose Gel-Digesting Preparation contains a unique...ENTRE for simple, quantitative recovery of intact ...els following electrophoresis in TAE, TBE, MOPS, o...tly in the TAE, TBE, MOPS, and phosphate electroph...
Hot StarTaq Master Mix Kit from QIAGEN
Biology Products: